(19)
(11) EP 1 041 149 B8

(12) CORRECTED EUROPEAN PATENT SPECIFICATION
Note: Bibliography reflects the latest situation

(15) Correction information:
Corrected version no 1 (W1 B1)

(48) Corrigendum issued on:
03.10.2007 Bulletin 2007/40

(45) Mention of the grant of the patent:
04.07.2007 Bulletin 2007/27

(21) Application number: 00105371.9

(22) Date of filing: 23.10.1995
(51) International Patent Classification (IPC): 
C12N 15/31(2006.01)
C07K 14/33(2006.01)
C07K 1/22(2006.01)
A61K 39/08(2006.01)
 C12N 1/21(2006.01)
C07K 16/12(2006.01)
A61K 38/16(2006.01)

(54)

Vaccine and antitoxin for treatment and prevention of C. difficile disease

Impfstoff und Antitoxine zur Behandlung und Vorbeugung von C. Difficile Krankheiten

Vaccin et antitoxines pour le traitement et la prévention de maladies causées par C. difficile

(84) Designated Contracting States:
AT BE CH DE DK ES FR GB GR IE IT LI LU MC NL PT SE
Designated Extension States:
LT LV SI

(30) Priority: 24.10.1994 US 329154
16.03.1995 US 405496
14.04.1995 US 422711
07.06.1995 US 480604

(43) Date of publication of application:
04.10.2000 Bulletin 2000/40

(62) Application number of the earlier application in accordance with Art. 76 EPC:
95937626.0 / 0796326

(73) Proprietor: ALLERGAN, INC.
Irvine, California 92612 (US)

(72) Inventors:
  • Williams, James A.
    Lincoln, NE 68516 (US)
  • Padhye, Nisha V.
    Lincoln, NE 68516 (US)
  • Thalley, Bruce S.
    Madison, WI 53719 (US)
  • Stafford, Douglas C.
    Madison, WI 53711 (US)
  • Firca, Joseph R.
    Vernon Hills, IL 60061 (US)
  • Kink, John A.
    Madison, WI 53717 (US)

(74) Representative: Glawe, Delfs, Moll 
Patentanwälte Rothenbaumchaussee 58
20148 Hamburg
20148 Hamburg (DE)


(56) References cited: : 
WO-A-94/13264
   
       
    Note: Within nine months from the publication of the mention of the grant of the European patent, any person may give notice to the European Patent Office of opposition to the European patent granted. Notice of opposition shall be filed in a written reasoned statement. It shall not be deemed to have been filed until the opposition fee has been paid. (Art. 99(1) European Patent Convention).